Phase 2 Evaluation of a Once Every 28 Days Dosing Regimen for LY573636-sodium in Patients With Metastatic Breast Cancer.
Latest Information Update: 23 Jul 2018
Price :
$35 *
At a glance
- Drugs Tasisulam (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 25 Jul 2011 Status changed from active, no longer recruiting to completed.
- 26 Aug 2010 Planned end date changed from 1 Apr 2011 to 1 Oct 2010 as reported by ClinicalTrials.gov.
- 01 Jul 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.